- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
JANSSEN RECEIVES CHMP POSITIVE OPINION FOR GUSELKUMAB RECOMMENDING APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE EUROPEAN UNION
Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23
Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight Influenza
Janssen and Biomedical Advanced Research and Development Authority (BARDA) join forces to accelerate new therapies and vaccines to protect communities against the threat of a pandemic
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Filing Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA® in Combination with Prednisone and Androgen Deprivation Therapy (ADT)
Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies
Shark Tank’s Daymond John to Judge the First Champions of Science “What’s New?” Challenge Multifaceted Platform to Broaden Public Engagement in Science
ACTELION RECEIVES FDA APPROVAL OF TRACLEER® (bosentan) FOR USE IN PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
--First PAH medication approved in the U.S. for pediatric patients aged three years and older--
Johnson & Johnson Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments
Memorandum of Understanding brings together best scientists from India and Johnson & Johnson to increase and accelerate pace of innovation needed to make TB history